Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Qishen Yiqi Drop Pill for endothelial function in coronary heart disease
ChiCTR2500100932Phase 4Not yet recruiting
- Sponsor
- Tongji Hospital
- Start
- Apr 2025
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of qishen yiqi drop pill in coronary arteriosclerosis (2 arms), sponsored by Tongji Hospital. Primary endpoint: Flow-Mediated Dilation. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
qishen yiqi drop pill
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on ChiCTR2500100932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500100932.